Saeed, Kordo, McLaren, Alex C., Schwarz, Edward M., Antoci, Valentin, Arnold, William V., Chen, Antonia F., Clauss, Martin, Esteban, Jaime, Gant, Vanya, Hendershot, Edward, Hickok, Noreen, Higuera, Carlos A., Coraça-Huber, Débora C., Choe, Hyonmin, Jennings, Jessica A., Joshi, Manjari, Li, William T., Noble, Philip C., Phillips, K. Scott, Pottinger, Paul S., Restrepo, Camilo, Rohde, Holger, Schaer, Thomas P., Shen, Hao, Smeltzer, Mark, Stoodley, Paul, Webb, Jason C.J. and Witsø, Eivind (2019) 2018 international consensus meeting on musculoskeletal infection: Summary from the biofilm workgroup and consensus on biofilm related musculoskeletal infections. Journal of Orthopaedic Research, 37 (5), 1007-1017. (doi:10.1002/jor.24229).
Abstract
Biofilm-associated implant-related bone and joint infections are clinically important due to the extensive morbidity, cost of care and socioeconomic burden that they cause. Research in the field of biofilms has expanded in the past two decades, however, there is still an immense knowledge gap related to many clinical challenges of these biofilm-associated infections. This subject was assigned to the Biofilm Workgroup during the second International Consensus Meeting on Musculoskeletal Infection held in Philadelphia USA (ICM 2018) (https://icmphilly.com).
The main objective of the Biofilm Workgroup was to prepare a consensus document based on a review of the literature, prepared responses, discussion and vote on thirteen biofilm related questions. The Workgroup commenced discussing and refining responses prepared before the meeting on day one using Delphi methodology, followed by a tally of responses using an anonymized voting system on the second day of ICM 2018.
The Working group derived consensus on information about biofilms deemed relevant to clinical practice , pertaining to: 1) surface modifications to prevent/inhibit biofilm formation, 2) therapies to prevent and treat biofilm infections, 3) polymicrobial biofilms, 4) diagnostics to detect active and dormant biofilm in patients, 5) methods to establish minimal biofilm eradication concentration for biofilm bacteria, and 6) novel anti-infectives that are effective against biofilm bacteria. It was also noted that biomedical research funding agencies and the pharmaceutical industry should recognize these areas as priorities.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.